Related Experiment Video

Updated: May 28, 2026

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction
08:41

Caspase-3 Activity in the Rat Amygdala Measured by Spectrofluorometry After Myocardial Infarction

Published on: January 12, 2016

Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive

Wei Jiang1, Harry Oken, Mona Fiuzat

  • 1Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. jiang001@mc.duke.edu

Journal of Cardiovascular Translational Research
|November 2, 2011
PubMed

Insights

Low levels of omega-3 fatty acids (FA) are linked to reduced survival in heart failure (HF) patients with major depressive disorder (MDD). Higher plasma omega-3 FA concentrations indicate a better prognosis for these patients.

Area of Science:

  • Cardiology
  • Nutritional Science
  • Psychiatry

Background:

  • Omega-3 fatty acids (FA) are crucial for cardiovascular health.
  • Low omega-3 FA levels are observed in coronary heart disease (CHD).
  • Omega-3 FA supplementation benefits patients with CHD and heart failure (HF).

Purpose of the Study:

  • To investigate the prognostic value of plasma omega-3 FA in HF patients with major depressive disorder (MDD).
  • To determine the association between omega-3 FA levels and survival in this specific patient group.

Main Methods:

  • Plasma samples from 109 HF patients with MDD were analyzed for FA methyl esters.
  • Flame ionization detection was used to quantify omega compounds.
  • Cox proportional hazards regression modeling analyzed survival outcomes.

Main Results:

  • Plasma total omega-3 FA was significantly associated with improved survival (HR 0.65, 95% CI 0.43-0.98).
  • Eicosapentaenoic acid (EPA) levels were also linked to better survival (HR 0.73, 95% CI 0.56-0.96).
  • Low plasma omega-3 FA emerged as a significant predictor of reduced survival.

Conclusions:

  • Plasma omega-3 FA levels hold prognostic value in HF patients with co-morbid MDD.
  • Maintaining adequate omega-3 FA may be important for survival in this population.
  • Further research into omega-3 FA's role in HF and MDD is warranted.

More Related Videos

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...